2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-16289R
    Lodoxamide tromethamine (Standard) 63610-09-3 98%
    Lodoxamide (tromethamine) (Standard) is the analytical standard of Lodoxamide (tromethamine). This product is intended for research and analytical applications. Lodoxamide tromethamine (U-42585E) is a medication for the treatment of prophylaxis of mast cell-mediated allergic disease.
    Lodoxamide tromethamine (Standard)
  • HY-163013
    Dicamba-5-hydroxypentanoic acid 2892008-29-4 98%
    Dicamba-5-hydroxypentanoic acid (DCo), synthesized from commercially available 5-hydroxy-dicamba, is an immunizing and heterologous hapten. Dicamba-5-hydroxypentanoic acid (DCo) is chemoselectively activated using one equivalent of DSC (N,N- disuccinimidyl carbonate).
    Dicamba-5-hydroxypentanoic acid
  • HY-163030
    LasB-IN-1 98%
    LasB-IN-1 (compound 5f) is a potent and orally active inhibitor of LasB (IC50 = 8.7 μM). LasB-IN-1 effectively attenuates elastase production and biofilm formation by P. aeruginosa while alleviating the inflammatory response through downregulating MAPK and NF-κB pathways. LasB-IN-1 is potential to be a novel anti-infective candidate against drug-resistant infections.
    LasB-IN-1
  • HY-163038
    Sulfamethoxazole-NO hydrate 98%
    Sulfamethoxazole-NO (SMX-NO) hydrate is the reactive metabolite of SMX (HY-B0322). Sulfamethoxazole-NO (SMX-NO) hydrate actis as a typical hapten and is capable of covalently modifying the MHC-peptide complex, can stimulate hapten-reactive T cells.
    Sulfamethoxazole-NO hydrate
  • HY-163057
    2,2',2''-Nitrilotris(NH-EG8-Lys-2,4-dinitroaniline) 929540-19-2 98%
    2,2',2''-Nitrilotris(NH-EG8-Lys-2,4-dinitroaniline) is a trivalent hapten. 2,2',2''-Nitrilotris(NH-EG8-Lys-2,4-dinitroaniline) can aggregate with monoclonal anti-2,4-DNP IgG (IgGDNP).
    2,2',2''-Nitrilotris(NH-EG8-Lys-2,4-dinitroaniline)
  • HY-163103
    (S)-Isomyosmine 67209-94-3 98%
    (S)-Isomyosmine is the S-enantiomer of Isomyosmine (HY-W701069). Isomyosmine is a nitrate reductase inhibitor. Isomyosmine is a nicotine related alkaloid present in solanecea plants containing nicotine. Isomyosmine can be used for research of inflammation and age-related disorders.
    (S)-Isomyosmine
  • HY-163122
    5-Formylsalicylic acid 616-76-2 99.54%
    5-Formylsalicylic acid (5-F-SA), a hapten, strongly upregulates MR1 expression (MR1 ligand).
    5-Formylsalicylic acid
  • HY-163179
    NLRP3-IN-28 2922814-80-8 98%
    NLRP3-IN-28 (compound N77) is a potent inhibitor of NLRP3. NLRP3-IN-28 inhibits Nigericin (HY-127019)-induced pyroptosis with an EC50 of 0.07μM. NLRP3-IN-28 alleviates the inflammatory reaction in vivo.
    NLRP3-IN-28
  • HY-163551
    BNP peptide/KLH 98%
    The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    BNP peptide/KLH
  • HY-163648
    Suloxifen 25827-12-7 98%
    Suloxifen is a thioketone compound, which exhibits anti-asthmatic efficacy.
    Suloxifen
  • HY-163843
    Antibacterial agent 234 98%
    Antibacterial agent 234 (6p) is an antibacterial agent. Antibacterial agent 234 (6p) exhibits good activity against Klebsiella pneumoniae with a MIC value of 6.25 µg/mL.
    Antibacterial agent 234
  • HY-163915
    8-(4-(Trifluoromethyl)anilino)quercetin 98%
    8-(4-(Trifluoromethyl)anilino)quercetin is a potent ErmA inhibitor. 8-(4-(Trifluoromethyl)anilino)quercetin has antioxidant and anti-inflammatory activity.
    8-(4-(Trifluoromethyl)anilino)quercetin
  • HY-164012
    Proxicromil 60400-92-2 98%
    Proxicromil is a derivative of chromone. Proxicromil is an orally active anti-asthmatic agent, and exhibits no liver toxicity.
    Proxicromil
  • HY-164068
    Cross-linked sodium hyaluronate gel 98%
    Cross-linked sodium hyaluronate gel is a biomaterial formed by cross-linking sodium hyaluronate. Cross-linked sodium hyaluronate gel has good moisturizing properties, viscoelasticity and biocompatibility. Cross-linked sodium hyaluronate gel can be used for the treatment of arthritis and the development of auxiliary materials in ophthalmic surgery.
    Cross-linked sodium hyaluronate gel
  • HY-164358
    α-Gracinoic acid 2180947-76-4 98%
    α-Gracinoic acid is an mPGES-1 inhibitor with anti-inflammatory activity.
    α-Gracinoic acid
  • HY-164361
    2′-Hydroxy-2,3-dimethoxychalcone 42220-80-4 98%
    α-Gracinoic acid is a Chalcone (HY-121054) derivative with anti-inflammatory activity. α-Gracinoic acid inhibits nitric oxide production catalyzed by inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-treated RAW 264.7 cells.
    2′-Hydroxy-2,3-dimethoxychalcone
  • HY-164395
    Sipuleucel-T 917381-47-6 98%
    Sipuleucel-T is a cancer vaccine. Sipuleucel-T recognizes prostatic acid phosphatase (PAP), present PAP antigens, and stimulates the immune response against prostate cancer cells.
    Sipuleucel-T
  • HY-164454
    AJI-100 844435-10-5 98%
    AJI-100 is a dual-target inhibitor of Aurora kinase A and JAK2 with IC50 values of 12.7 nM and 18.5 nM, respectively. AJI-100 directly blocks Aurora kinase A to inhibit T cell mitosis and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-100 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD).
    AJI-100
  • HY-164455
    AJI-214 1395886-20-0 98%
    AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD).
    AJI-214
  • HY-164480
    GTCpFE 1588866-45-8 98%
    GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44+ CD24- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers.
    GTCpFE
製品番号 製品名 / Synonyms Application Reactivity